HEXO Stock: Is the Cannabis Giant a Buy Right Now?

Down 95% from all-time highs, HEXO stock continues to remain a high-risk bet for growth investors.

| More on:
edit Jars of marijuana

Image source: Getty Images

Shares of Canadian cannabis giant HEXO (TSX:HEXO)(NASDAQ:HEXO) rose by over 10% in the first half of 2021. However, since then, the stock has wiped off these gains and is now down over 50% year to date. The cannabis stock is now down 95% from record highs, burning significant investor wealth in the process.

Generally, you look at a company’s revenue and earnings growth to make an investment decision. But it’s difficult for cannabis companies to keep delivering top-line growth and earnings improvement, as the industry is grappling with a wide array of structural issues. Further, the cannabis industry is at a nascent stage, which has attracted several players, thereby increasing competition resulting in a price war to capture market share.

So, marijuana producers, including HEXO, have been hit by widening losses, which have led to multiple equity capital raises in the past, resulting in an accelerated dilution of shareholder wealth in recent years.

Investors also need to consider a company’s cash flow from operations to see if the entity is burning through cash with respect to day-to-day activities, which will then result in further shareholder dilution and a corresponding decline in stock price. For example, in August 2021, HEXO stock lost over 25% in a single trading session after the company announced its plan to raise over $175 million via an equity offering.

HEXO stock remains vulnerable

In the last 12 months, HEXO has burnt close to $20 million to fund its operational activities. In its fiscal third quarter of 2021 (ended in July), HEXO reported a cash balance of $194 million, which provides the company with enough leeway to improve its cash flows in the future. However, HEXO has been on an acquisition spree this year and disclosed three big-ticket acquisitions in the first five months of 2021. These acquisitions will be funded via a combination of company stock and cash, both of which will weigh on HEXO’s already weak financials.

Investors who are bullish on HEXO stock will argue that the company’s acquisition of Redecan, which is the largest privately held cannabis producer in Canada, will allow the former to gain significant traction in Canada’s recreational marijuana market. But can HEXO afford to keep raising capital and fund its expansion plans?

Similar to other Canadian cannabis producers, HEXO is also eyeing expansion south of the border for when pot is legalized at the federal level. A few months back, HEXO acquired a cannabis facility in Colorado for $6 million. But it will spend around $50 million to upgrade the facility, which is a matter of grave concern.

What’s next for HEXO stock?

HEXO is currently valued at a market cap of $603 million. The company has increased its revenue from just $4.9 million in fiscal 2018 to $80.78 million in fiscal 2020. But its operating losses have also widened from $17.9 million to $163 million in this period. If interest rates rise, it will negatively impact HEXO’s balance sheet, as the company has already paid $11 million in interest and financing expenses in the last 12 months, accounting for almost 10% of total sales in this period.

HEXO might continue to raise debt to fund its acquisition plans, which suggest the marijuana company has to reduce cash burn at a rapid clip to gain investor confidence. Despite the company’s less-than-impressive financials, Bay Street expects HEXO stock to more than double to $5.51 per share in the next 12 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends HEXO Corp.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »